GLR Partners’s ResMed RMD Stock Holding History

GLR Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$562K	Buy	2,883 +162	+6%	+$33.6K	0.26%	61
2026 Q1	$611K	Buy	+2,721	New	+$678K	0.33%	55

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

GLR Partners's RMD Position: Q2 2026 in Review

GLR Partners increased its ResMed (RMD) stake by 6% in Q2 2026, buying an estimated $33.6K and bringing the position to 2,883 shares worth $562K. The position accounts for 0.26% of the portfolio, ranked #61.

GLR Partners first reported a position in RMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $611K in Q1 2026. 879 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

GLR Partners held 2,883 shares of ResMed worth $562K as of Q2 2026.
GLR Partners bought 162 ResMed shares in Q2 2026, an estimated $33.6K.
ResMed made up 0.26% of GLR Partners's portfolio in Q2 2026, its #61 holding.
GLR Partners first reported a position in ResMed in Q1 2026 and has held it in 2 quarters since.
GLR Partners's ResMed position peaked at $611K in Q1 2026.
879 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on GLR Partners's 13F filing for Q2 2026, filed 27 Jul 2026.